Decoy Therapeutics Regains Nasdaq Listing Compliance, Averting Delisting

summarizeSummary

Decoy Therapeutics Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a prior delisting threat and ensuring continued listing on The Nasdaq Capital Market.

check_boxKey Events

• Nasdaq Compliance Regained

  On March 31, 2026, the Nasdaq Hearings Panel confirmed that Decoy Therapeutics Inc. has regained compliance with the Minimum Bid Price Requirement and all other applicable listing requirements.

• Delisting Threat Averted

  This confirmation resolves the prior notice of non-compliance received on December 31, 2025, and averts a potential delisting from The Nasdaq Capital Market.

• Reverse Stock Split Instrumental

  The company implemented a reverse stock split, effective March 6, 2026, which was key to achieving the required bid price of at least $1.00 for 10 consecutive business days by March 20, 2026.

• Mandatory Panel Monitor Imposed

  Decoy Therapeutics will be subject to a Mandatory Panel Monitor until March 31, 2027, meaning any future non-compliance with the bid price requirement could lead to a delisting determination.

auto_awesomeAnalysis

Decoy Therapeutics Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, a critical development following a prior delisting notice and a recent 10-K filing that expressed substantial doubt about the company's ability to continue as a going concern. This resolution, achieved through a reverse stock split and sustained trading above the $1.00 threshold, removes an immediate existential threat to the company's public trading status. While the company will remain under a Mandatory Panel Monitor until March 31, 2027, this news provides a crucial lifeline, especially as the stock trades near its 52-week lows, indicating the company is actively addressing its operational challenges.